Cryo-Cell International, Inc.
Cryo-Cell International, Inc. (NYSE American: CCEL) provides cellular processing and cryogenic storage, primarily for families preserving newborns’ umbilical cord blood and cord tissue stem cells, and also operates a public cord blood bank. Its services are marketed to expectant parents, with referrals from healthcare… From the company’s description.
Over the twelve months to Aug 31, 2026, Cryo-Cell International, Inc. reported revenue of $31.13M, down 2.0% from a year earlier, and a net loss of $1.95M. Its operating margin was 0.6%, and operations generated $4.92M in cash. In fiscal 2025, it reported revenue of $31.57M, down 1.3% from fiscal 2024, and a net loss of $2.43M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cryo-Cell International, Inc. does
In the company’s own words
Cryo-Cell International, Inc. (NYSE American: CCEL) provides cellular processing and cryogenic storage, primarily for families preserving newborns’ umbilical cord blood and cord tissue stem cells, and also operates a public cord blood bank. Its services are marketed to expectant parents, with referrals from healthcare professionals; public units are distributed to transplant centers through the National Marrow Donor Program. The company also manufactures PrepaCyte CB, a processing system for umbilical cord blood, and offers third-party biological storage services through ExtraVault. It reports three segments: family-use processing and storage, PrepaCyte CB manufacturing, and public-use processing and storage. Through global affiliates, Cryo-Cell stores more than 250,000 cord blood and cord tissue specimens worldwide. The company was incorporated in 1989 and describes itself as the first private cord blood bank to separate and store stem cells, beginning in 1992. Its planned expansion into infusion clinics and biopharmaceutical manufacturing under a Duke University license is on hold following termination of the agreement. Its website is www.cryo-cell.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Health Services
- Headquarters
- OLDSMAR, FL
- Fiscal year end
- November
- CIK
- 862692
- SIC
- 8090
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cryo-Cell International, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cryo-Cell International, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cryo-Cell International, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cryo-Cell International, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cryo-Cell International, Inc.'s last four quarterly filings that the numbers alone won't show?”